Names and pronunciation
(kriz-oh′ti-nib) Xalkori
PDF page 322
Loading InternPractice…
Drug reference
(kriz-oh′ti-nib) Xalkori
PDF page 322
Func. class.: Antineoplastic
PDF page 322
USES: Locally advanced or meta- static non–small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test
PDF page 322
CONTRAINDICATIONS: Preg- nancy, breastfeeding, hypersensitivity, concurrent use of strong CYP3A4 induc- ers/inhibitors Precautions: Neonates, infants, chil- dren, adolescents, pneumonitis, severe hepatic disease, congenital long QT syn- drome, severe renal impairment, end- stage renal disease, vision disorders
PDF page 322
DOSAGE AND ROUTES • Adult: PO 250 mg bid; continue as long as beneficial; if CCr <30 mL/min use 250 mg daily
PDF page 322
Available forms: Capsules 200, 300 mg
PDF page 322
• Adult: PO 250 mg bid; continue as long as beneficial; if CCr <30 mL/min use 250 mg daily
PDF page 322